Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The use and performance of productivity scales to evaluate presenteeism in mood disorders.
Despiégel N, Danchenko N, François C, Lensberg B, Drummond MF. Despiégel N, et al. Among authors: danchenko n. Value Health. 2012 Dec;15(8):1148-61. doi: 10.1016/j.jval.2012.08.2206. Value Health. 2012. PMID: 23244819 Review.
Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G, Danchenko N, Despiegel N, Marteau F. Nordström G, et al. Among authors: danchenko n. Value Health. 2012 Mar-Apr;15(2):231-9. doi: 10.1016/j.jval.2011.09.011. Epub 2012 Jan 27. Value Health. 2012. PMID: 22433753
Cost-Utility of Vortioxetine in the Treatment of Major Depressive Disorder: Comparison with Agomelatine, Bupropion, Sertraline and Venlafaxine in the Finnish Setting.
Soini EJ, Hallinen T, Brignone M, Despiégel N, Aalto-Setälä M, Danchenko N, Kolasa K. Soini EJ, et al. Among authors: danchenko n. Value Health. 2014 Nov;17(7):A459. doi: 10.1016/j.jval.2014.08.1267. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201284 No abstract available.
Challenges in measuring and valuing productivity costs, and their relevance in mood disorders.
Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Lensberg BR, et al. Among authors: danchenko n. Clinicoecon Outcomes Res. 2013 Nov 18;5:565-73. doi: 10.2147/CEOR.S44866. eCollection 2013. Clinicoecon Outcomes Res. 2013. PMID: 24273412 Free PMC article. Review.
Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N. Wade AG, et al. Among authors: danchenko n. Pharmacoeconomics. 2008;26(11):969-81. doi: 10.2165/00019053-200826110-00008. Pharmacoeconomics. 2008. PMID: 18850765 Clinical Trial.
Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder.
Lam RW, Lamy FX, Danchenko N, Yarlas A, White MK, Rive B, Saragoussi D. Lam RW, et al. Among authors: danchenko n. Neuropsychiatr Dis Treat. 2018 Oct 29;14:2861-2877. doi: 10.2147/NDT.S175188. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 30464471 Free PMC article.
The effect of vortioxetine on health-related quality of life in patients with major depressive disorder.
Florea I, Danchenko N, Brignone M, Loft H, Rive B, Abetz-Webb L. Florea I, et al. Among authors: danchenko n. Clin Ther. 2015 Oct 1;37(10):2309-2323.e6. doi: 10.1016/j.clinthera.2015.08.008. Epub 2015 Sep 4. Clin Ther. 2015. PMID: 26346592 Clinical Trial.

FINDINGS: Vortioxetine produced significantly better results compared with placebo in the SF-36 mental component summary score (5 mg: 2.6, P = 0.001, SES of 0.22, n = 604; 10 mg: 4.8, P < 0.001, SES of 0.42, n = 328) and 4 domain scores (vitality, social function

FINDINGS: Vortioxetine produced significantly better results compared with placebo in the SF-36 mental component summary score (5 mg: 2.6, P …
Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder.
Xie F, Despiegel N, Danchenko N, Hansen K. Xie F, et al. Among authors: danchenko n. Int J Psychiatry Clin Pract. 2009;13(1):59-69. doi: 10.1080/13651500802450506. Int J Psychiatry Clin Pract. 2009. PMID: 24946123
The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.
Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. Florea I, et al. Among authors: danchenko n. Brain Behav. 2017 Feb 2;7(3):e00622. doi: 10.1002/brb3.622. eCollection 2017 Mar. Brain Behav. 2017. PMID: 28293465 Free PMC article.
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, Aalto-Setälä M, Danchenko N, Koponen H, Kolasa K. Soini E, et al. Among authors: danchenko n. Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):293-302. doi: 10.1080/14737167.2017.1240617. Epub 2016 Oct 21. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 27680105
35 results
Jump to page
Feedback